Bulletin
Investor Alert

Market Pulse Archives

July 21, 2021, 6:46 a.m. EDT

Johnson & Johnson beats earnings estimates for Q2 and raises full-year guidance

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Johnson & Johnson (JNJ)
  • X
    Dow Jones Industrial Average (DJIA)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Johnson & Johnson shares /zigman2/quotes/201724570/composite JNJ +1.46% rose 1.1% in premarket trade Wednesday, after the consumer and health company beat earnings estimates for the second quarter and raised its full-year guidance. The company said it had net income of $6.278 billion, or $2.35 a share, up from $3.626 billion, or $1.36 a share, in the year-earlier period. Adjusted per-share earnings came to $2.48, ahead of the $2.29 FactSet consensus. Sales rose 27.1% to $23.312 billion from $18.336 billion, also ahead of the $22.490 billion FactSet consensus. Chief Executive Alex Gorksy said sales were strong across the company's medical device, consumer health and pharma businesses. Consumer health sales rose 13.5 to $3.735 billion, pharma sales rose 17.2% to $12.599 billion and medical device sales rose 62.7% to $$6.978 billion. The company raised its full-year guidance and now expects adjusted EPS to range from $9.50 to $9.60, up from prior guidance of $9.30 to $9.45. It expects sales of $92.5 billion to $93.3 billion including its COVID-19 vaccine, versus prior guidance of $89.3 billion to $90.3 billion. Shares have gained 7% in the year to date, while the Dow Jones Industrial Average /zigman2/quotes/210598065/realtime DJIA -0.17% has gained 12.8%.

/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 159.38
+2.29 +1.46%
Volume: 8.75M
Dec. 3, 2021 4:00p
P/E Ratio
23.82
Dividend Yield
2.66%
Market Cap
$419.58 billion
Rev. per Employee
$613,918
loading...
/zigman2/quotes/210598065/realtime
US : Dow Jones Global
34,580.08
-59.71 -0.17%
Volume: 444.85M
Dec. 3, 2021 5:35p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.